During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Organon OGN shares soared 8.5% in the last trading session to close at $12.64. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of ...

Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence, from Biogen. The move is set to bolster and widen ...

JERSEY CITY, N.J. - Organon (NYSE: OGN), a global healthcare company, has acquired the U.S. regulatory and commercial rights for TOFIDENCE™, a biosimilar to ACTEMRA®, from Biogen Inc. (NASDAQ: BIIB), ...

NEW YORK — Zohran Mamdani, the most left-leaning candidate in this summer’s mayoral election, rolled out a public safety plan Tuesday that hinges on launching a new city agency tasked ...